Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results

BioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant, yet modest” success in a Phase 3 trial. The drugmakers ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

One in three young adults use AI chatbots for drug and alcohol information, study finds

Researchers warn that chatbots could spread misinformation about substance use, as a survey finds that one in three young adults in the United States are turning to AI for drug-related information.

  • 32% of US young adults aged 18-29 used AI chatbots for drug and alcohol information
  • 12% of users consulted AI weekly or daily for substance-related queries
  • Black respondents were 2.52 times more likely to use AI for substance info than white respondents

More from Monday 26 October →